CyPath® Lung Sales Surge 200% Year-Over-Year as Adoption Accelerates
Event summary
- CyPath® Lung sales doubled year-over-year, reaching a new record in Q2 2026.
- Q2 2026 sales grew 30% sequentially from Q1 2026.
- Nearly 3,000 CyPath® Lung tests performed since commercial launch.
- Expanding physician adoption across pulmonology practices and VA facilities.
The big picture
bioAffinity's CyPath® Lung is gaining traction as a noninvasive diagnostic tool, addressing the growing need for accurate early-stage lung cancer detection. The company's strategy focuses on increasing utilization among existing clients while expanding into new markets. This momentum positions bioAffinity to capitalize on the rising number of patients with indeterminate pulmonary nodules, driven by expanded lung cancer screening and incidental findings from other procedures.
What we're watching
- Market Expansion
- Whether bioAffinity can sustain this growth pace as it enters new markets and expands its sales footprint.
- Clinical Validation
- The impact of the large-scale longitudinal clinical study on further adoption and reimbursement discussions.
- Pipeline Development
- How quickly bioAffinity can advance its R&D pipeline for asthma and COPD diagnostics to diversify revenue streams.
Related topics